Clinical Trial ECOGBRES1207


Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer. e3 Breast Cancer Study- evaluating everolimus with endocrine therapy.

Principal Investigator(s)

Julie Means-Powell


  • Protocol No. ECOGBRES1207
  • Open Date: 10/31/2013
  • Staging: Phase III
  • Age Group: Adults
  • Scope: National
  • Objective: The primary objective of this study is to compare whether the addition of one year of everolimus (10 mg daily) to standard adjuvant endocrine therapy improves invasive disease-free survival (IDFS) in patients with high-risk, hormone-receptor (HR) positive and HER2-negative breast cancer.
  • Disease Sites:
  • Therapies: Molecular Targeted Agents / Immunotherapy / Biologics
  • Drugs: Anastrozole; Everolimus (RAD001); Exemestane; Goserelin acetate (Zoledex); Letrozole (Femara); Leuprolide acetate (Lupron); Tamoxifen
  • Participating Institutions: Vanderbilt University
  • National Clinical Trial ID: NCT01674140
  • Secondary Protocol No: S1207



Learn More

You do not have JavaScript enabled. This site works better with JavaScript turned on.